Accéder au contenu
Merck

Studies on gambogic acid (IV): Exploring structure-activity relationship with IκB kinase-beta (IKKβ).

European journal of medicinal chemistry (2012-04-05)
Haopeng Sun, Feihong Chen, Xiaojian Wang, Zongliang Liu, Qian Yang, Xiaojin Zhang, Jia Zhu, Lei Qiang, Qinglong Guo, Qidong You
RÉSUMÉ

Previously we have reported a series of gambogic acid's analogs and have identified a compound that possessed comparable in vitro growth inhibitory effect as gambogic acid. However, their target protein as well as the key pharmacophoric motifs on the target have not been identified yet. Herein we report that gambogic acid and its analogs inhibit the activity of IκB Kinase-beta (IKKβ) through suppressing the activation of TNFα/NF-κB pathway, which in turn induces A549 and U251 cell apoptosis. IKKβ can serve as one of gambogic acid's targets. The preparation of the compounds was carefully discussed in the article. Caged 4-oxa-tricyclo[4.3.1.0(3,7)]dec-2-one xanthone, which was identified as the pharmacophoric scaffold, represents a promising therapeutic agent for cancer and useful probe against NF-κB pathway.